OBJECTIVE: The vascular damage systemic sclerosis (SSc) consists mainly of … In systemic
lupus erythematosus (SLE), autoantibody to lipoprotein lipase (LPL), a key enzyme that …

… Antilipoprotein lipase (anti-LPL) antibodies have recently … as systemic lupus erythematosus
(SLE), systemic sclerosis (SSc), polymyositis and rheumatoid arthritis [1]. Lipoprotein lipase …

… Antibodies to LPL occurred in 47% of SLE patients and in a similar percentage of patients
with polymyositis or systemic sclerosis. The prevalence of these antibodies was less in …

… concluded that antibodies directed against LPL were not disease-specific because they
occurred as frequently in patients with polymyositis and progressive systemic sclerosis as they …

… in systemic lupus erythematosus has been widely reported. Anti-lipoprotein lipase antibody
… OBJECTIVE: To assess the extent of coronary risk due to autoimmune antibodies in terms of …

… Anti-LPL antibodies were also described in systemic sclerosis, … systemic sclerosis study,
the authors could demonstrate that anti-LPL antibodies were capable to inhibit lipoprotein lipase …

… Recombinant human anti-transforming growth factor beta1 antibody therapy in systemic
sclerosis: a multicenter, randomized, placebocontrolled phase I/II trial of CAT-192. Arthritis …

… hormone-sensitive lipase activity, … with antibodies against Fli1, adipsin and β-actin. (C)
Chromatin was isolated from HDMECs and immunoprecipitated using rabbit anti-Fli1 antibody or …

… I antibody was further evaluated by immunoblotting analysis. To determine the functional
relevance of anti-Prx I antibody in vivo , we assessed whether anti-Prx I antibody … -Prx I antibody …

… in 38% of patients with systemic LED [11], and a similar prevalence was found in subjects
with systemic sclerosis and dermatomyositis, reaching 67% in patients with systemic LED [12]. …